{{item.videoDuration}}
{{item.title}}
{{item.text}}
{{item.videoDuration}}
{{item.title}}
{{item.text}}
Key strategies for global pharma companies to reduce risk and drive growth in the China market
To listen to all PwC Next in Health podcasts, click here. Subscribe and listen to all episodes at your convenience via any device at Apple Podcasts and Spotify.
Overview
Tune in to hear PwC specialists discuss their recently published article: How a local-first strategy in China can help global pharma and life sciences players reduce risk and drive growth. Topics include:
- Sharing key strategies for pharma companies contemplating localization in China, offering valuable insights on maximizing business growth while mitigating risks in the Chinese market
- Three approaches organizations can consider to competing at a local level in China
- Impacts to different functions across the value chain such as R&D, supply chain, and IT
Topics: Pharma, pharma and life sciences, pharmaceutical and life sciences, patients, shareholders, regulators, operations, innovation, strategy, global pharma and life sciences, China strategy, regulations, compliance, commercial market, economical labor, agility, sustainability, CRM, supply chains, med devices and equipment, value chain, IT, R&D, manufacturing
{{filterContent.facetedTitle}}
{{contentList.loadingText}}
{{contentList.loadingText}}
Contact us
Follow us
